News

An RVC Biofund Portfolio Company's Development to Detect Lung Damage in COVID-19 Patients Was Successfully Tested
The RVC Biofund closed the deal to sell its 17.79% stake in the Genetico portfolio company Center for Genetics and Reproductive Medicine (hereinafter — Genetico).
According to the results of the assessment of the investment portfolio of RVC as of the end of the third quarter of 2020, the return on capital indicator (TVPI) exceeded the figure of one.
On October 30, Deputy General Director — Investment Director of RVC Alexey Basov spoke at the plenary session of the 14th Siberian Venture Fair “Venture Industry — Who and In Which Way Invests in Biotech and Pharma?”.
GamesBoost42, a global start-up finance company, has opened a $5 million credit line for the portable mini projector manufacturer Cinemood. Pinewood (on the Russian market — “Multikubik”) is part of the Russian-Belarusian Venture Investment Fund portfolio and the Far East High-Tech Fund, created with RVC capital participation.
The management company S-Group Capital Management, managing the property of the closed-end investment fund of incredibly risky (venture) investments — S-Group Ventures, made a deal to exit the Russian manufacturer of thermoelectric micromodules (TEMM) RMT, LLC.
On October 15, Deputy General Director — the Investment Director of RVC, Alexey Basov, spoke at the Bank of Russia's second strategic session to discuss the Consultative Report "Development of Alternative Investment Mechanisms: Direct Investment and Crowdfunding." The event was dedicated to the issues of venture investors' exit from technology projects.
On September 23, the 12th Russian Private Equity Congress and the 8th Venture Investors Forum took place in Moscow. RVC supported the event as an official partner. Representatives of development institutions, venture funds, and the regulator discussed the necessary steps for the growth of the private equity and venture capital industry in Russia, including removing barriers to entering a new class of institutional investors into the market.
The Center for Genetics and Reproductive Medicine Genetics, a resident of Skolkovo and a portfolio company of the RVC Bio fund, has developed the test named Onconetix to search for mutations in a tumor and began its implementation into practice with partner clinics.
On June 30, the 11th annual forum of innovative InfoSpace technologies, organized by the Initiative Center for Business Support and Development, took place. Deputy General Director - Investment Director of RVC Aleksei Basov spoke at the plenary session “Digital Leadership. Strategies, Human Resources, Technologies” with a report on the current situation in the venture capital market and on measures to support RVC for technology companies.
RVC has provided its annual report for 2019. It reveals the main results of the company's activities in developing the venture capital market, supporting the National Technology Initiative, and implementing the national program “Digital Economy of the Russian Federation”.


1 2 3 4 5 ... 12 Next
News for 2021: January

Search by name:

Search by date:

Select date in calendar
Select date in calendar
Venue: